locationhoogl.blogg.se

1. #Auxl historic stock price full#
2. #Auxl historic stock price registration#
3. #Auxl historic stock price license#

We look forward to our future as an independent company, and to your support as a Baudax Bio shareholder as we begin this new I invite you to learn more about Baudax Bio by reviewing the enclosed information We intend to have Baudax common stock listed on the Nasdaq Our goal is to leverage our drug development expertise to develop these productĬandidates for use in hospital and acute care settings. Our early-stage product pipeline includes proprietary product candidates for use in anesthesia (neuromuscular blockade and reversal). Leveraging our development experience to progress our other pipeline productĬandidates. We believe that our development expertise and unique productĬandidates make us an attractive partner to potential strategic collaborators. We intend to pursue strategic collaborations with other pharmaceutical companies to develop and commercialize IV meloxicam outside of the United States. We anticipate completing the Phase IIIb program during 2019.Įntering into strategic partnerships to maximize the potential of IV meloxicam and other product candidates Phase IIIb program that includes clinical trials in colorectal surgery patients and orthopedic surgery patients. We previously established sales management, marketing and reimbursement functions in anticipation of theĬommercialization of IV meloxicam in the United States and we believe we can utilize these preparations for the successful commercialization of an acquired or licensed product.Įxpanding data supporting benefits of IV meloxicam. We are currently evaluating IV meloxicam in a We are seeking in-license or acquisition opportunities to add commercial or near-commercial products to our portfolio.

#Auxl historic stock price license#

Pursuing the license or acquisition of additional products. IV meloxicam for the management of moderate to severe pain. Our key goal is to obtain FDA approval of In addition to our pipeline, we continue to evaluate acquisition, out-licensing and in-licensing opportunities.Ĭompleting regulatory approval of IV meloxicam.

#Auxl historic stock price registration#

We believe we can create value for our shareholders through the development, registration and commercialization of injectable meloxicam and our other Our lead product candidate, injectable meloxicam, to the hospital and related acute care markets. We believe that we can bring valuable therapeutic options for patients, prescribers and payers, such as On behalf of the entire Baudax Bio team, I am pleased to welcome you as a future shareholder of our new company.īaudax Bio will be a clinical-stage biopharmaceutical company focused on developing and commercializing innovative products for hospital It describes the separation in detail and contains important information about Recro and Baudax Bio.

Please read the attached information statement, which is being shared with all Recro shareholders as of the record date for the distribution. You do not need to take any action to receive the common stock of Baudax Bio to which you are entitled as a Recro shareholder as of the record date. Under the terms of the distribution, each Recro shareholder will receive one share of Baudax Bio common stock for every two and one-half shares of RecroĬommon stock held of record on November 15, 2019, the record date for the distribution.

Separation, Baudax Bio will be spun out of Recro and established as an independent company.

Well-positioned with the resources, talent and foundation to be industry leaders in their respective fields. Through this separation, we have the potential to create two focused, durable businesses that are

#Auxl historic stock price full#

Therapeutic options for patients, prescribers and payers to the hospital and related acute care markets.īest way to realize the full potential of this separation is for Recro and Baudax Bio to operate independently, with distinct business strategies. The new company, which has been named Baudax Bio, Inc., or Baudax Bio, will focus on bringing valuable The strategic objectives of the separation are to unlock value by enhancing operational performance and strategic flexibility and tailoring theĬapital structures to best serve these distinct businesses.įollowing the separation, Recro Pharma, Inc., or Recro, expects to focus on its CDMO activities. In August 2019, we announced a transformative milestone for Recro — our intent to separate our contract development and manufacturing, orĬDMO, business from our acute care business, thereby creating two independent, publicly traded companies.